Actoprotector research
Drugs studied for preserving physical work capacity under stress, including the adamantane derivative Bromantane and the benzimidazole Bemitil.
Browse study findings by subject ↓
Filter Bemitil topics
Findings from selected studies
- Bemitil during a sea voyage
Of 298 maritime operators, 148 received Bemitil and 150 placebo. The paper reports 6.7% shorter simple reaction time and 13.7% greater static endurance. Detailed tests involved a subset of 20.
62 of 62 Bemitil topics
About the Bemitil topic map
Some publications cover several research topics. “Archive target” marks a citation whose original report is unavailable.
Physical work capacity
Human reportControlled-workload monograph material is linked as a starting point. It includes combination arms; it does not establish general enhancement or synergy.
Combined extreme conditions
Human reportA combined heat/gas volunteer abstract and historical guidance are located. The English abstract has a monoxide/dioxide inconsistency; original methods remain necessary.
Recovery after acute physical fatigue
Human reportControlled-workload monograph material is linked as a starting point. It includes combination arms; it does not establish general enhancement or synergy.
Chronic asthenic symptoms
Human reportPatient comparisons and pharmacokinetic correlations are recovered as indexed abstracts. Allocation, full outcomes and independent replication remain unresolved.
Mental and operator workload
Human reportThe voyage abstract reports operator measures. Kim’s combination research is a separate dissertation trail; its original methods remain pending.
Historical military operations
Historical accountThese sources describe operational history. Contemporary documents establishing the deployment details and treatment effects are unavailable.
Show 56 more Bemitil topics
Long maritime voyages
Human reportThe 1991 voyage abstract is distinct from the later naval teaching manual. Complete cohort and allocation details are still needed.
Heat and overheating
Human reportA combined heat/gas volunteer abstract and historical guidance are located. The English abstract has a monoxide/dioxide inconsistency; original methods remain necessary.
Altitude and hypoxia
Human reportMetaprot plus Ladasten was studied after ascent to high altitude. No isolated-component arm is described in the abstract; not a synergy or altitude-illness-prevention finding.
Cold exposure
Archive targetThe B-300 dissertation describes a combination. The original cold-adaptation proceedings would be needed to identify a Bemitil-only comparison.
Antarctic wintering
Historical accountThese sources describe operational history. Contemporary documents establishing the deployment details and treatment effects are unavailable.
Sports recovery
Archive targetThe original study and its methods are unavailable.
Occupational noise and hearing-loss prevention
Patent reportA patent reports 148 noise-exposed workers in three unequal groups. Randomization, blinding and exposure comparability are not established.
Sensorineural hearing loss
Archive targetGlaznikov’s hearing section concerns occupational hearing. Prevention and treatment of established hearing loss are distinct outcomes.
Combined interventions for chronic hearing loss
Patent reportPatent combines Bemitil, dalargin and acupuncture. Case material does not isolate the effect of any component.
Vestibular dysfunction
Archive targetThe original study and its methods are unavailable.
Statokinetic and operator resistance
Archive targetThe original study and its methods are unavailable.
Progressive muscular dystrophy
Human reportSmall neuromuscular reports (21 and 22 patients) address biochemical changes. Cohort overlap and durable functional outcomes need checking.
Myotonia and secondary amyotrophies
Human reportRelated neuromuscular abstracts are linked. Specific myotonia and secondary-amyotrophy subgroup findings still require original reports; do not generalize progressive-dystrophy findings.
Psychiatric and neurological asthenia
Human reportPatient comparisons and pharmacokinetic correlations are recovered as indexed abstracts. Allocation, full outcomes and independent replication remain unresolved.
Chronic hepatitis
Human reportHuman liver-cell measurements changed, but structural abnormalities persisted and measures did not normalize. This is not demonstrated reversal of liver disease.
Hepatitis A rehabilitation
Archive targetThe 1993 issue contains a hepatitis A rehabilitation citation lead. Original methods and clinical outcomes remain pending.
Liver disease of different etiologies
Archive targetThe original study and its methods are unavailable.
Cirrhosis
Human reportHuman liver-cell measurements changed, but structural abnormalities persisted and measures did not normalize. This is not demonstrated reversal of liver disease.
Liver-associated immune dysfunction
Archive targetThe original study and its methods are unavailable.
Pneumonia combination research
Archive targetThe original study and its methods are unavailable.
Chronic respiratory failure
Archive targetThe original study and its methods are unavailable.
Acute myocardial infarction
Archive targetThe original study and its methods are unavailable.
Ischemic heart disease
Archive targetThe original study and its methods are unavailable.
Coronary artery bypass surgery
Archive targetA conference citation identifies the CABG report. The accessible record gives no study design or clinical outcome.
Major surgery and hysterectomy
Archive targetThe original study and its methods are unavailable.
Fetal hypoxia and gestosis
Archive targetThe pregnancy/gestosis lead remains unverified. No pregnancy safety or treatment recommendation is supported here.
Emergency responders
Historical accountRecovered historical guidance is not a contemporary safety standard or a controlled emergency-response trial.
Chernobyl rehabilitation
Dissertation contextAn author’s abstract discusses rehabilitation after Chernobyl. Full clinical methods and the earlier Yagupov report remain pending; this is not proof of radioprotection.
Armenian earthquake response
Historical accountThese sources describe operational history. Contemporary documents establishing the deployment details and treatment effects are unavailable.
Acute hypoxic hypoxia
Animal / laboratoryRat pressure-chamber experiments measured glutathione-related biochemical responses. These endpoints do not establish human hypoxia protection.
Glutathione systems
Animal / laboratoryRat pressure-chamber experiments measured glutathione-related biochemical responses. These endpoints do not establish human hypoxia protection.
Lipid peroxidation
Human reportA small neuromuscular patient study examined lipid peroxidation and erythrocyte membranes. Biomarker change is not a general clinical benefit.
Antioxidant enzymes
Animal / laboratoryRat pressure-chamber experiments measured glutathione-related biochemical responses. These endpoints do not establish human hypoxia protection.
Brain responses to hypoxia
Animal / laboratoryRat intermittent-hypoxia work links brain metabolic measures to the experimental adaptation model.
Cerebral hemorrhage models
Archive targetThe original study and its methods are unavailable.
Seizure models
Archive targetThe original study and its methods are unavailable.
Central nervous system trauma
Archive targetThe original study and its methods are unavailable.
Myocardial ischemia models
Archive targetThe original study and its methods are unavailable.
Reperfusion models
Archive targetThe original study and its methods are unavailable.
Acute heart-failure models
Archive targetThe original study and its methods are unavailable.
Intestinal ischemia and shock
Archive targetThe original study and its methods are unavailable.
Peritonitis and mucosal repair
Archive targetThe original study and its methods are unavailable.
Liver regeneration after hepatectomy
Archive targetThe original study and its methods are unavailable.
Toxic liver injury
Dissertation contextAn author’s abstract describes toxic-injury experiments. Model-specific results do not validate human antidote combinations or self-treatment.
PCB and ethanol liver-injury models
Dissertation contextAn author’s abstract describes toxic-injury experiments. Model-specific results do not validate human antidote combinations or self-treatment.
Organophosphate injury models
Dissertation contextAn author’s abstract describes toxic-injury experiments. Model-specific results do not validate human antidote combinations or self-treatment.
Dichloroethane injury models
Archive targetThe original study and its methods are unavailable.
Ethylene glycol injury models
Archive targetThe original study and its methods are unavailable.
Nitrite injury models
Dissertation contextAn author’s abstract describes toxic-injury experiments. Model-specific results do not validate human antidote combinations or self-treatment.
Red-cell recovery
Archive targetThe original study and its methods are unavailable.
Membrane stability
Human reportA small neuromuscular patient study examined lipid peroxidation and erythrocyte membranes. Biomarker change is not a general clinical benefit.
Bronchopulmonary inflammation models
Archive targetThe original study and its methods are unavailable.
Immune and inflammatory models
Archive targetThe original study and its methods are unavailable.
Gonadal adverse effects
Animal / laboratoryProlonged exposure reduced sexual activity and a spermatogenesis measure in rats. This is a safety signal requiring follow-up, not human risk quantification.
Pregnancy and development in animals
Archive targetOriginal Bemitil developmental studies are still needed. Bromantane developmental findings must not be transferred to Bemitil.
CYP450 and drug metabolism
Animal / laboratoryRat enzyme induction, cultured human lymphocytes and rat-urine metabolite analysis concern metabolism. They do not establish safe human interactions.
Hypoxen / Olifen ↗
Environmental stress, mitochondrial experiments, toxicology and historical combination research.
ADAMANTANE DERIVATIVEBromantane / Ladasten ↗
Development lineage, patient trials, operator studies, dopamine-related mechanisms and preclinical safety findings.
BENZIMIDAZOLE DERIVATIVEBemitil / Metaprot ↗
Asthenia, maritime and hearing research, neuromuscular reports, liver metabolism and unresolved archival programs.
Updated evidence, original methods and remaining gaps ↗
Bromantane and Bemitil: evidence comparison
| Compound / formulation | Context | Source type | Interpretation limits |
|---|---|---|---|
| Ladasten + Sydnocarb | Animal swimming performance and heat exposure | Separate experimental reports, 2006Source record ↗ | Single drugs outperformed the combination in swimming; a separate heat study was favorable. Effects are model-specific, not evidence of universal synergy. |
| Bromantane / Ladasten | Patient asthenia versus rested or fatigued volunteers | Randomized patient trial, uncontrolled multicenter report and small laboratory comparisonsSource record ↗ | Clinical symptoms and performance measures answer different questions. Duplicate multicenter reports are grouped. |
| Bemitil / Metaprot | Asthenia, neuromuscular and occupational research | Human reports, patent-reported hearing comparison, animal and metabolism studiesSource record ↗ | Full methods and independent replication remain uneven. Biomarker changes are not proven clinical recovery. |
| Bemitil + Bromantane | Combined heat/gas exposure | 1993 volunteer comparison plus 1996 guidanceSource record ↗ | The abstract has a monoxide/dioxide translation inconsistency. Historical findings are not exposure-safety guidance. |
| Metaprot + Ladasten | Short-term high-altitude adaptation | 2014 volunteer comparison with hypoxen and placeboSource record ↗ | No isolated-component arms described; neither synergy nor altitude-illness prevention established. |
| Bromitil | Combined-tablet pharmacokinetics | 2009 dissertation abstract; animal experimentsSource record ↗ | Formulation identity is documented there. Current product equivalence, human benefit and safe ratios are not established. |
Trekrezan in rat endurance and muscle assays
A 60-rat patent experiment reported loaded swim times of 33.50 minutes with saline and 48.00 and 52.30 minutes with 10 and 25 mg/kg Trekrezan. The same filing reports PGC‑1α and mitochondrial DNA measurements.
Patent methods and all arm results ↗ · Trekrezan research profile ↗
Assessing the evidence
Reports are not independent trials
The Ladasten multicenter reports share the same cohort description. The small Bemitil neuromuscular papers may overlap. Bibliography length is not a measure of replicated effectiveness.
A patent is a different source
The occupational hearing comparison is a patent-reported cohort. The Ladasten patent documents a proposed new use of Bromantane. Neither patent status nor publication establishes clinical efficacy.
Sources to locate or review
Dissertation abstracts, indexed abstracts, original text and unlocated documents have explicit labels. Claims about heat protection, military deployment and emergency use require supporting original documents.
Additional archival references
Source-linked studies appear on the compound profiles and in the main bibliography. These additional records include dissertations, books, patents and proceedings—including documents that remain unrecovered.
Substituted N-adamantylamines — author’s certificate 860446
Earlier certificate cited by a recovered patent; original pendingCited in the original Ladasten patent. The proposed 21 April 1980 priority date awaits the original certificate; publication and invention dates must not be conflated.
Bibliography record ↗Adamantane precursors: ADK-638, ADK-910 and ADK-918
Archive target · original not recoveredADK-638, Chlodantane and the benzamide compounds belong to distinct branches. Certificate 740752 and papers from 1979 and 1986 are cited in accounts of their development.
Bibliography record ↗Pharmacokinetics of Bromantane
Archive target · original not recoveredA later author bibliography cites S. A. Medvedkova, Moscow 1984, 19 pages; the earlier G. A. initials conflict. Authenticate the original catalogue before entering pharmacokinetic estimates.
Bibliography record ↗Mechanisms of action of adamantane derivatives with protective effects under extreme conditions
Archive target · original not recoveredThe dissertation citation gives no original methods, population or comparator tables.
Bibliography record ↗Mechanisms of stress-protective action of Bromantane and Chlodantane
Library catalogue verified; original scan appraisal pendingRussian State Library record 01000029984 confirms A. R. Khalimov, Ufa 1997, 22 pages; the earlier Yu. Sh. attribution was incorrect. Original scan appraisal and endocrine findings remain unresolved.
Bibliography record ↗Pharmacological correction of operator-skill learning during intense physical workload
Archive target · original not recoveredUnverified lead comparing piracetam, Bemitil and Bromantane. The reported July 1994 instruction and later Captain NEMO / Yagupov links require original documents.
Bibliography record ↗Mechanisms of Ladasten’s psychostimulant, anxiolytic and immunotropic activity
Author’s abstract · Russian transcription and PDF linkAuthor’s abstract and its associated mechanistic program located. The 44-page abstract is not the complete 336-page dissertation. Rat-brain and cell findings do not establish human clinical effects.
Bibliography record ↗Pharmacology of Adamantanes
Book cited by recovered patent; book not recoveredThe Ladasten formulation patent cites this book as historical background. The patent does not describe a trial from the book.
Bibliography record ↗Study of heat-protective effects of Bromantane at various levels of overheating
Publisher page with PDF link · PDF not yet inspectedPublisher page offers the original Russian PDF. Indexed abstract checked; original heat protocols and ambiguous English wording still need appraisal. This is the same source as PMID 7793100, not another study.
Bibliography record ↗Bemitil: Main Results of Clinical Study and Prospects for Use
Archive target · original not recoveredThe proceedings and the Bobkov–Vinogradov recommendations are identifiable from citations. The individual study designs remain uncertain.
Bibliography record ↗Pharmacological Correction of Fatigue
Archive target · original not recoveredThe book and Smirnov mechanism chapter remain acquisition targets. Full bibliographic transcription and original chapter retrieval remain pending.
Bibliography record ↗Bemitil dossier — Physiologically Active Substances, issue 25
Archive target · original not recoveredThe issue covers mechanisms, operator workload, neuromuscular disease, occupational hearing, hepatitis A and intestinal ischemia. Page numbers differ between citations.
Bibliography record ↗Antihypoxants and Actoprotectors: Results and Prospects
Archive target · original not recoveredCABG, pediatric croup and other clinical leads trace to proceedings. Original reports, enrollment, allocation and outcomes remain unresolved.
Bibliography record ↗Naval, Antarctic and emergency-response Bemitil records
Archive target · original not recoveredArchival leads include 1993 naval chapters, 1996 Marine Medical Journal, Antarctic wintering and Chernobyl rehabilitation. Operational use narratives are not controlled efficacy evidence. See the separately linked 1991 voyage study and recovered scan, 2015 naval manual and 1996 rescue guidance.
Bibliography record ↗Broader clinical Bemitil archive: liver, heart, lungs, surgery and pregnancy
Archive target · original not recoveredPreserves the reported clinical leads without turning them into established indications. This includes gestosis/fetal hypoxia, major surgery, respiratory failure and rehabilitation; no pregnancy or condition-specific safety conclusion follows.
Bibliography record ↗Bemitil preclinical archive: ischemia, poisoning, repair and reproductive effects
Archive target · original not recoveredTargets include cerebral and myocardial injury, intestinal ischemia, peritonitis, hepatectomy, convulsions, chemical exposures and developmental toxicology. Models and formulations must be checked separately; class-level findings cannot be assigned to Bemitil automatically.
Bibliography record ↗New approaches to pharmacological correction of nonspecific components of toxic injury
Author’s abstract · Russian web transcriptionAuthor’s abstract transcription identifies Bromitil as a combined Bromantane–Bemitil tablet studied in animals, and describes toxic-injury and Chernobyl-rehabilitation work. OCR has an inconsistent title-page year; metadata and defense text indicate 2009. Complete thesis and raw data not reviewed.
Bibliography record ↗Bemitil, dalargin and acupuncture for chronic sensorineural hearing loss — RU2223741C1
Patent text located · individual case descriptionsPatent describes a multi-component intervention and case material. It cannot isolate Bemitil’s effect. Separate from Glaznikov’s occupational-noise prevention patent.
Bibliography record ↗Ladasten multicenter report — related record PMID 21322821
English abstract · related cohort reportSame title, 28-center / 728-patient cohort and abstract as PMID 20559263. Retained as a related publication, not an additional independent trial.
Bibliography record ↗Study findings by subject
119 source records
2021 · Comparison in people
Trekrezan in 130 adults with acute respiratory viral infections
In an open comparison of 130 adults, respiratory symptoms resolved an average of 2.2 days sooner in the Trekrezan group.
2023 · Comparison in people
Trekrezan in adults and adolescents with acute respiratory viral infections
Adolescent fever lasted 2.5 days less with Trekrezan. At days 3–5, fatigue persisted in 47.3% of treated adults and 70% of adult controls drawn from the earlier study.
2021 · Comparison in people
Trekrezan in 80 outpatients with fatigue after COVID-19
After eight days, 32 of 40 Trekrezan recipients and 8 of 40 controls had no fatigue on the study scale. The 2021 and 2022 reports describe the same 80 patients.
No asthenia · 32/40 (80%) vs 8/40 (20%) · Day 8
2022 · Comparison in people
Trekrezan in 103 inpatients with ongoing symptoms after COVID-19
Mean MFI-20 fatigue scores fell from 44.5 to 31.9 with add-on Trekrezan and from 41.2 to 36.7 in the comparison group. Hospital stays averaged 11.4 vs 12.5 days.
MFI-20 fatigue score · 44.5 ± 13.9 to 31.9 ± 9.5 vs 41.2 ± 13.1 to 36.7 ± 6.4 · Days 8–10 · Table 2 lists p<0.001 without identifying the contrast in the table header.
2006 · Animal research
Trekrezan and Polyoxidonium in experimental bronchopulmonary inflammation
Both preparations were associated with lower lactate and higher pyruvate and ATP in blood lymphocytes and lung tissue.
2008 · Animal research
Metabolic effects of Trekrezan during adaptation of rats to intermittent hypoxic hypoxia
Trekrezan was associated with stronger adaptive metabolic changes in brain, heart and liver during a three-day hypoxic-training experiment.
2006 · Animal research
Efficiency of Trekrezan in experimental bronchopneumonia in rats
The abstract reports altered lymphocyte immune measures, lower lactate and higher ATP and pyruvate in lung tissue and blood lymphocytes.
2009 · Animal research
Pharmacology of the immunomodulator Trekrezan
The dissertation transcription compares Trekrezan, Metaprot and Polyoxidonium, including combinations. Trekrezan plus Metaprot produced larger changes in selected energy-metabolism and immune endpoints than either alone.
2014 · Review of earlier studies
Pharmacology of Trekrezan, a new immune modulator and adaptogen
Reviews immune, inflammatory and metabolic mechanisms, including Trekrezan/Metaprot combinations in rat models.
2007 · Review of earlier studies
Trekrezan: founder of a new class of adaptogens and immunomodulators
A chemistry and development anchor covering immune, stress and tissue-repair research branches.
2004 · Comparison in people
Bemitil after surgery for lung abscesses
The dissertation reports recovery or improvement in 82.6% of 23 patients receiving Bemitil plus postoperative care versus 60.0% of 25 receiving postoperative care alone.
2005 · Randomized study in people
Bemitil and immune markers in chronic hepatitis
At day 21 in the noncirrhotic subgroup, CD3+ counts were 829.52 versus 628.84 cells/µL with placebo, while CD19+ counts were 59.85 versus 159.32 cells/µL.
1991 · Animal research
Bemitil and related compounds in a mouse macrophage assay
Bemitil and two related compounds increased macrophage phagocytic measures in mice. The 5-ethoxy derivative had the largest reported effect.
2015 · Animal research
Antioxidant Effect of Polyoxidonium and Metaprot during Bronchopulmonary Inflammation in Rats.
In rat bronchopulmonary inflammation, combined Polyoxidonium and Metaprot showed a greater antioxidant effect than either alone. In macrophage assays, the direction of the biochemiluminescence response depended on concentration.
2014 · Animal research
[Features of bemithyl pharmacokinetics upon inhalation administration].
The report compared inhaled, intragastric and intravenous pharmacokinetics and identified metabolites. The authors favored inhalation on pharmacokinetic grounds; the abstract does not identify the study population or establish clinical safety.
2012 · Animal research
[Protective effects of metaprot and ethomerzol in carbophos intoxications].
In carbophos-intoxicated rats, Metaprot improved swimming and selected biochemical measures. Ethomerzol was more effective in the reported tests.
2011 · Laboratory analysis
[Pharmacokinetics of domestic actoprotector drug Metaprot in healthy volunteers].
After oral Metaprot in healthy adults, mean time to peak concentration was about one hour. The report describes substantial variability and a multimodal distribution of pharmacokinetic parameters.
Peak concentration · 0.91 ± 1.05 micrograms/mL
2008 · Animal research
[Effects of phytoecdysteroids and bemithyl on functional, metabolic, and immunobiological parameters of working capacity in experimental animals].
In mouse and rat swimming experiments, turkesterone and cyasterone showed stronger effects on work duration and recovery than the bemithyl comparator.
2008 · Animal research
[Modification of impulse activity of cat brainstem monoaminergic cells caused by bemitil].
Bemitil modified noradrenergic and serotonergic brainstem-neuron activity in cats, with dose-dependent effects.
2007 · Animal research
[Correlative interconnections between impulse activity of aminergic neurons of the brainstem and spectral components of electroencephalogram during action of bemitil].
In five cats, Bemitil altered correlations between brainstem neuronal firing and cortical electrical activity.
2006 · Animal research
Distribution of bemitil in organs and tissues of rats after single or repeated administration.
Rat tissue measurements detected Bemitil in several organs. The authors interpreted repeated-exposure findings as accumulation in blood rather than tissues; human accumulation was not assessed.
1995 · Comparison in people
[The stimulation of pulmonary epithelial regeneration and of the clearance function of the mucociliary apparatus by using bemetil].
The abstract describes a method intended to promote bronchial epithelial regeneration and mucociliary function with Bemitil, including immunocorrection. It does not supply population, group sizes or numerical results.
2006 · Animal research
[Studying the hepatoprotector effect of bemithyl on a model of chronic toxic liver damage].
In experimental rat cirrhosis, bemithyl improved selected liver-function, antioxidant and histological measures and reduced fibrosis severity.
2003 · Lab research
[Membrane mechanisms of effects of antihypoxic agents bemethyl and almide on neurons of Mollusca].
In isolated mollusk neurons, bemithyl and almide reversibly blocked ion currents in a concentration-dependent manner. Proposed systemic antihypoxic effects were not established by these cell experiments.
Reversible ion-channel block · 100–1,000 microM concentration range
2005 · Observational study
[Efficacy of bemithyl and pyrazidol in patients with cerebroasthenia due to brain injury].
A clinical report described reduced asthenic symptoms and changes in oxidative-stress measures with combined bemithyl and pyrazidol after brain injury.
2004 · Animal research
Cerebroprotective effect of combined treatment with pyrazidol and bemitil in craniocerebral trauma.
In rats after brain trauma, Bemitil and pyrazidol had model-dependent individual effects; combined treatment was reported to have additive behavioral and metabolic effects.
2004 · Animal research
[The influence of hepatoprotector 2-ethylthiobenzimidazole hydrobromide (bemithyl) on the content of glycogen in cirrhotic rat liver hepatocytes located in various microenvironments].
In cirrhotic rat liver, bemithyl-associated glycogen changes differed between hepatocytes within lobules and the wider cell population.
2003 · Animal research
Effects of the 2-ethylthiobenzimidazole hydrobromide (bemithyl) on carbohydrate metabolism in cirrhotic rat liver.
In cirrhotic rat liver, bemithyl reduced glycogen content and altered glycogen-related enzyme activity. These are metabolic findings rather than clinical liver outcomes.
1991 · Animal research
[The action of bemitil on the self-regulation systems during short-term immobilization].
In immobilized rats, the authors reported changes toward normal in motor, cardiovascular and stress-related measures after bemithyl.
2002 · Animal research
Antioxidant effects of Bemitil during acute cerebral hypoxia.
In acute hypoxic hypoxia in rats, Bemitil limited brain lipid peroxidation and suppression of antioxidant-system activity.
2002 · Animal research
[The effect of bemithyl in rats with experimental pneumonia].
In experimental rat pneumonia, bemithyl reduced mortality frequency, lung lactate accumulation and lipid peroxidation.
2000 · Animal research
[Effects of bemethyl, ethomersol, and yakton on the liver regeneration after partial hepatectomy].
The experimental report described faster liver regeneration and changes in biochemical and morphological measures after partial hepatectomy with bemithyl, etomerzol or yakton. The abstract does not specify the species.
2000 · Animal research
[Acute toxicity of bemithyl and bromithyl].
Acute rat toxicity testing found different lethal-dose estimates and dose-dependent physiological effects for bemithyl and bromithyl. The preparations should not be treated as equivalent.
Bemitil LD50 · 581.48 mg/kg; interval 350.17–965.57
1999 · Controlled study in people
[Effect of bemithyl (bemactor) on the bronchial epithelium regeneration and the main protector mechanisms of the respiratory system in chronic inflammation].
The respiratory-inflammation report found no direct bemithyl effect on the evaluated mucociliary and local bronchial-defense mechanisms. Its proposal for a specialized application requires the original methods.
1999 · Animal research
[The effect of bemitil on conditioned-reflex memory in normal rats and under stress exposures].
Bemitil improved conditioned-reflex learning in rat experiments and was reported to attenuate stress-related disruption.
1998 · Comparison in people
[A new approach to the therapy of pyoderma in servicemen: the use of the actoprotector bemitil].
A report involving 51 men with pyoderma described better recovery and selected immune and local inflammatory measures with Bemitil-containing treatment than conventional care.
Clinical recovery · 86.3 ± 4.8% · Conventional therapy: 62.1 ± 6.8%
1995 · Animal research
[Changes in the activity of an epileptogenic focus in the rat hippocampus under the influence of bemitil].
Bemitil pretreatment suppressed activity of an experimentally induced hippocampal epileptogenic focus in male rats.
1997 · Observational study
[The effect of bemitil on the parameters of lipid peroxidation and nitrogen metabolism in epilepsy in children].
A small pediatric epilepsy report described reductions in oxidative-stress markers and seizure frequency in some children receiving Bemitil. Outcomes in two children could not be evaluated.
Erythrocyte malondialdehyde · 3.34 ± 1.13 → 1.57 ± 0.61 micromol/L · Control 1.58 ± 0.96 · p<0.05
1991 · Observational study
[The dynamics of the immunological indices during the treatment of recurrent erysipelas with the new immunostimulant bemitil].
An adjunctive erysipelas report described higher T-lymphocyte numbers and IgA/IgM levels during Bemitil treatment, without absolute immune-marker values or a clinical effect size.
1987 · Animal research
[Bemetil pharmacokinetics in an experiment on rats].
Rat pharmacokinetic experiments found rapid systemic appearance after intragastric dosing, a peak around one hour and elimination largely through metabolites or bound forms rather than unchanged drug.
Time to peak after intragastric dosing · Approximately 1 hour
1991 · Study involving people
[Effect of bemitil on metabolic processes and work capacity at high altitude].
The paper examined metabolism and physical work capacity at high altitude during Bemitil exposure. Its indexed citation gives no measurements or comparison-group results.
1987 · Laboratory analysis
[Experimental and clinical data on the ability of bemetil to penetrate the hemato-encephalic barrier].
Bemitil concentrations exceeded plasma concentrations in rat brain tissue. In brain-injury patients, cerebrospinal-fluid concentrations were below plasma concentrations. The two measurements do not establish equivalent human brain exposure.
1987 · Animal research
[Effect of bemetil on the perception of visual stimuli].
The paper examined visual perception during Bemitil exposure. The indexed citation does not report the visual task, group sizes or direction of change.
1989 · Animal research
[Antihypoxic and antioxidative properties of bemitil].
Rat and tissue experiments reported reduced lipid-peroxidation changes during hypoxia. The report also found no antiradical activity, distinguishing antioxidant-associated outcomes from direct radical scavenging.
1990 · Animal research
[Changes in the nature of the time concordance of the functional brain structures under the influence of bemitil].
This paper examined whether Bemitil altered the timing of activity across brain structures. The indexed citation supplies no recording results.
1986 · Animal research
[Mutagenic and antimutagenic properties of bemitil].
The tested genetic-toxicology assays did not detect the specified mutations or chromosomal damage, and mouse experiments found reduced damage from selected alkylating agents. This does not establish comprehensive human safety.
1987 · Animal research
[Structural analysis of the functional status of the brain as affected by bemethyl using pattern recognition theory].
In trained cats, visual evoked potentials and cluster analysis suggested altered coordination among functional brain systems after bemethyl.
1988 · Comparison in people
Use of the new psychotropic preparation Bemitil in treating asthenic disorders
Compared Bemitil with piracetam and pyrithioxine. The authors report earlier and greater changes in asthenic symptoms with Bemitil.
1986 · Observational study
Pharmacokinetics and the clinical effect of Bemitil after a single administration
Plasma kinetic curves differed between clinical-response patterns after a test administration.
1991 · Observational study
The role of Bemitil pharmacokinetics in realizing its therapeutic efficacy
Reports correlations between selected pharmacokinetic parameters and overall clinical response.
2002 · Animal research
Effect of bemethyl on the glutathione system in the rat liver in acute hypoxia
Reports preservation of glutathione-related measures and enzyme activities. Actinomycin D inhibition experiments implicate an RNA-dependent process.
2005 · Animal research
Bemithyl potentiates the antioxidant effect of intermittent hypoxic training
Reports changes in brain metabolism and resistance to hypoxia after combined intermittent exposure and Bemitil.
2021 · Laboratory analysis
Investigation of Bemethyl Biotransformation Pathways by Combination of LC–MS/HRMS and In Silico Methods
Identifies nine metabolites with six molecular formulas in rat urine and proposes biotransformation pathways involving glutathione conjugation.
1991 · Observational study
Mechanisms of the therapeutic effect of Bemitil in neuromuscular diseases
Examined lipid peroxidation and erythrocyte-membrane permeability during Bemitil treatment.
1992 · Comparison in people
Use of Bemitil in patients with progressive muscular dystrophies
Reports changes in lipid peroxidation and discusses glucose metabolism in patients receiving Bemitil.
2002 · Comparison in people
Effect of bemethyl on glycogen metabolism in hepatocytes of diseased human liver
Reports changes in glycogen content and composition versus basic therapy. Structural liver abnormalities persisted and metabolic indices did not normalize.
Glycogen decrease versus glucose-6-phosphatase activity · r = 0.75 · p<0.05
2002 · Animal research
Bemethyl and cytochrome P450: rat liver and human lymphocytes
Reports mixed-type hepatic enzyme induction in rats and concentration-dependent enzyme-activity changes in cultured human lymphocytes.
2010 · Randomized study in people
The antidepressant properties of Ladasten: a pilot study
CGI-I response was reported in 66.7% versus 80%; the between-group difference was not significant. All 30 completed treatment.
CGI-I response at eight weeks · 66.7% Ladasten versus 80% escitalopram; p>0.05
2012 · Comparison in people
[Ladasten versus placebo effect self-evaluated by neurasthenia patients with different EEG alpha rhythm types].
Subjective and objective responses to Ladasten and placebo differed across EEG-defined neurasthenia subgroups. Higher subjective responses were not confined to active treatment.
2011 · Comparison in people
[Self-evaluation of single test doses and objective indices of ladasten vs. placebo efficacy in neurasthenic patients].
Patients with neurasthenia rated single-dose Ladasten tolerability similarly to placebo. The authors examined associations between self-ratings, baseline characteristics and subsequent treatment response.
2011 · Randomized study in people
[Ladasten in the management of non-motor symptoms of Parkinson's disease].
The publication concerns Ladasten (Bromantane) for nonmotor symptoms of Parkinson’s disease. The indexed citation gives no group sizes, symptom scores or comparator.
2010 · Observational study
[Prospects for using ladasten preparations in patients with irritable bowel syndrome].
The abstract describes Ladasten use in patients with irritable bowel syndrome and asthenic symptoms but provides no sample size, comparison details or numerical outcomes.
2008 · Observational study
[Characteristics of ladasten effect in neurasthenia patients with various EEG parameters].
Anxiety-asthenia patients with different EEG alpha-rhythm patterns showed different clinical and EEG responses to Ladasten. The abstract does not establish a validated treatment-selection biomarker.
2006 · Observational study
[Pilot clinical trial of ladasten].
An early clinical report describes stimulant and anxiolytic effects in patients with psychogenic asthenia. The abstract does not provide sample size, allocation details or numerical treatment effects.
2010 · Observational study
Treatment of asthenic disorders in patients with psychoautonomic syndrome: results of a multicenter study on efficacy and safety of ladasten]
Reports symptom and quality-of-life improvements during 28 days of Ladasten treatment and follow-up. The abstract reports adverse events in 3% and discontinuation in 0.8%.
CGI-S responders · 76.0%
2009 · Comparison in people
Effect of ladasten on the psychophysiological parameters of healthy volunteers]
The authors report psychophysiological changes during mental fatigue, with larger effects in stress-labile participants.
2012 · Animal research
Bromantane and splenic T-cell populations after 20 days of social stress in mice
Splenic CD3+ cells were 31.3% with Bromantane versus 27.9% with saline and 32.0% in unstressed controls. Thymus mass remained low in both stressed arms.
1996 · Animal research
Bromantane and cellular immune responses in experimental models
The authors reported increased delayed skin hypersensitivity and maturation of precursor T cells, with partial prevention of selected immune changes in NZB mice.
1996 · Animal research
Bromantane and antibody-producing cells in mice
Bromantane increased the number and activity of antibody-producing B cells in mice. The authors also reported increased IgM production in induced immune-deficit models.
2000 · Animal research
[Effect of bromantane on the rat neurologic status in two month course].
Two-month rat exposure produced dose- and sex-dependent changes in movement, exploration, temperature and body weight. The authors reported no clear dependence-related behavior during follow-up; this is not evidence of absent human dependence risk.
2014 · Animal research
Correcting effect of ladasten on variations in the subpopulation composition of T lymphocytes in C57BL/6 mice on the experimental model of an anxious-depressive state.
In the 30-day social-stress model, Ladasten shifted immune organ weights and T-cell populations toward control values. A related 2012 paper used a 20-day model and reported persistent low thymus mass.
2000 · Animal research
[The effect of bromantane on the cardiovascular and sympathetic-adrenal systems in animals].
Animal experiments found changes in cardiac output, heart rate, vascular resistance and catecholamine responses. These physiological effects do not establish cardiovascular benefit in people.
2000 · Animal research
[An acute toxicity study of bromantane].
Acute animal toxicity testing characterized dose-dependent behavioral effects. The authors proposed different catecholaminergic and cholinergic contributions at different exposures.
2001 · Animal research
[Complex evaluation of the effect of bromantane on animal behavior].
The authors applied statistical methods to rat open-field behavior to evaluate neurological toxicity. The abstract does not provide a numerical effect estimate.
1999 · Animal research
[The effect of bromantane on the behavior of inbred mouse strains with different phenotypes of emotional stress reaction].
Bromantan altered open-field and elevated-plus-maze behavior differently across mouse strains, supporting a strain-dependent anxiolytic-like response.
1999 · Animal research
[The characteristics of the neuropsychotropic activity of bromantane in laboratory animals].
The report describes behavioral activation, EEG changes and learning-related effects in laboratory animals.
Mouse IP LD50 · 8,100 mg/kg
2011 · Animal research
Effect of ladasten on the content of cytokine markers of inflammation and behavior of mice with experimental depression-like syndrome.
In an LPS-induced mouse model, Ladasten reduced elevated TNF-alpha and IL-6 and attenuated behavioral disturbances. This is distinct from a clinical depression trial.
2012 · Animal research
Mechanisms of action of ladasten: activation of gene expression for neurotrophins and mitogen-activated kinases.
The study examined ERK signaling and neurotrophin gene expression in rat brain regions after Ladasten. The abstract does not state the direction or magnitude of the individual results.
2011 · Animal research
[Effect of antiasthenic drug ladasten on the level of cytokines and behavior in experimental model of anxious depression in C57BL/6 male mice].
In socially stressed male mice, Ladasten reduced selected inflammatory cytokines and attenuated behavioral and immune-organ changes.
1995 · Animal research
[The effect of bromantane on the dopamin- and serotoninergic systems of the rat brain].
Acute and chronic exposure altered serotonin and dopamine-related measures across rat brain regions, with different regional directions of response.
2010 · Animal research
[Neurochemical study of effects of the new anxiolytic drugs afobazol and ladasten on the synthesis and metabolism of monoamines and their metabolites in the brain structures of Wistar rat on the model of monoamine synthesis blockade induced by aromatic amino acid decarboxylase inhibitor NSD-1015].
Under experimental blockade of monoamine synthesis, Ladasten increased L-DOPA in several rat brain regions and altered dopamine-metabolism indices. Effects differed from the afobazole comparator.
Afobazole-only serotonin changes · 5-HT up to +50%, precursor up to +60%, metabolite up to +50% · These percentages are NOT Ladasten effects
2010 · Animal research
Proteomic analysis and identification of ladasten target proteins in rat brain.
Proteomic analysis identified 13 rat-brain proteins with altered expression after a single Ladasten exposure. Identification of expression changes does not establish direct drug binding to those proteins.
2010 · Animal research
[Role of the brain dopaminergic and serotoninergic systems in psychopharmacological effects of ladasten and sydnocarb].
The experiments found no direct effects on the tested dopamine and serotonin receptors, but reported increased dopamine synthesis and release and inhibition of dopamine transport in rat preparations.
Dopamine-transport inhibition IC50 · Ladasten 3.56 microM; Sydnocarb 28.66 nM · Different concentration units retained
2009 · Animal research
Changes in CREB (SER133) content and DNA-binding activity of transcriptional factors in rat brain cells against the background of ladasten exposure.
The study examined phosphorylated CREB and transcription-factor DNA-binding activity in rat brain regions. The abstract does not quantify individual effects.
2007 · Animal research
The effects of ladasten on dopaminergic neurotransmission and hippocampal synaptic plasticity in rats.
Ladasten altered dopamine-synthesis measures in rats and reinforced short-term synaptic potentiation in hippocampal preparations. Protein-synthesis inhibition blocked this reinforcement; dopamine-receptor antagonism attenuated it.
2006 · Animal research
[Cytosine demethylation in the tyrosine hydroxylase gene promoter in the hypothalamus cells of the rat brain under the action of an aminoadamantane derivative Ladasten].
After a single Ladasten exposure, rat hypothalamic cells showed increased cytosine demethylation at selected regulatory sites of the tyrosine-hydroxylase gene. The authors proposed a connection with increased transcription.
2006 · Animal research
[Thermoprotector properties of a combination of sydnocarb with ladasten].
A Sydnocarb–Ladasten combination showed thermoprotective effects and increased cerebral blood flow and respiration in experimental animals.
Thermoprotector response · Significant with 20 + 20 mg/kg · Numerical survival/temperature effect size not supplied
2006 · Animal research
[Comparative study of the effect of Ladasten, Sydnocarb and their combination on physical work ability of laboratory animals].
In a mouse swimming test, the individual drugs produced more pronounced and longer-lasting performance effects than the Ladasten–Sydnocarb combination. The result does not support universal combination synergy.
2005 · Animal research
[Studying the mechanisms of ladasten action].
Ladasten produced an anxiolytic-like effect in one rat stress-response phenotype but not the other, and prevented stress-related changes in benzodiazepine-site binding in the responsive strain.
2005 · Animal research
Psychotropic effects of sidnocarb and ladasten in inbred mice with different reaction to emotional stress.
Behavioral effects varied by mouse strain and exposure. Ladasten alone and in combination with Sidnocarb produced different patterns of activation.
Combination · Ladasten 10 mg/kg plus Sydnocarb 6 or 12 mg/kg
2002 · Animal research
Toxic effect of single treatment with bromantane on neurological status of experimental animals.
Acute rat testing showed stimulation at lower tested exposures and behavioral suppression and other toxicity signs at higher exposures. Temperature and sensory responses also changed.
Behavioral stimulation range · 30–300 mg/kg
2005 · Animal research
The effect of ladasten on gene expression in the rat brain.
Researchers examined gene expression in rat brain after Ladasten exposure. The indexed citation does not identify the affected genes or report the direction of change.
1998 · Animal research
[Comparative analysis of effects of adapromine, midantan, and bromantane on the bioelectric activity of the rat brain].
A rat study compared brain electrical activity after adapromine, midantan and Bromantane. The indexed citation provides no recordings or quantitative comparison.
1999 · Animal research
[Analysis of pharmacological properties of bromantane].
The publication examines Bromantane’s pharmacological properties. The indexed citation has no abstract identifying the experimental model or outcomes.
1995 · Animal research
[Correlated interconnection between pharmacokinetic and dynamic development of the pharmacologic effects of bromantane].
The paper examined the relationship between Bromantane exposure over time and its pharmacological effects. The indexed citation gives no concentration or effect estimates.
1995 · Animal research
[The effect of bromantane, a new immunostimulant with psychostimulating action, on release and metabolism of dopamine in the dorsal striatum of freely moving rats: a microdialysis study].
Researchers used microdialysis in freely moving rats to study dopamine release and metabolism in the dorsal striatum after Bromantane. The indexed citation does not report the direction or size of the changes.
1995 · Study involving people
Study of heat-protective effects of bromantane at various levels of overheating
The abstract describes model-dependent heat responses, including narrowed heat-tolerance ranges alongside favorable dynamometry and hemodynamic findings under a different heat-load setting.
1998 · Animal research
The effect of bromantane on the physical work capacity of laboratory animals]
Reports sustained physical-performance changes and less mitochondrial alteration following repeated extreme exercise.
Physical-work performance · 1.3–1.6 times the effect of optimal-dose phenamine · Animal experiment
2000 · Animal research
Effects of bromantane and sidnocarb on long-term operant conditioning and its vegetative correlates in rats]
Bromantane and sydnocarb changed operant performance differently. Bromantane was associated with fewer errors and fewer total responses.
1993 · Animal research
A quantitative pharmaco-electroencephalographic analysis of the action of bromantane]
Quantitative EEG analysis describes prolonged, biphasic changes after Bromantane.
2004 · Animal research
Ladasten induces the expression of genes regulating dopamine biosynthesis in various structures of rat brain]
Reports changes in tyrosine hydroxylase and DOPA-decarboxylase gene expression alongside dopamine and L-DOPA measurements.
2004 · Animal research
The effect of ladasten on the activity of cAMP-dependent protein kinases and the phosphorylation of proteins in brain cells of rats]
Examines cAMP-dependent kinase activity and phosphorylation during the early period after Ladasten exposure.
2004 · Animal research
Effect of ladasten on the proteinase C activity in the rat brain cells]
Examines calcium-dependent signaling and protein kinase C activity after Ladasten.
2005 · Animal research
DNA macroarray analysis of gene expression changes in rat brain after single administration of 2-aminoadamantane compound]
Reports altered expression of a subset of genes related to signaling, cytoskeleton, synaptic proteins and metabolism.
2011 · Animal research
Time course of histone deacetylase 1 and acetylated H3 and H4 histones in the brain of rats treated with ladasten
Reports changes in HDAC1 and acetylated histones after a single Ladasten exposure.
1999 · Animal research
The effect of bromantane on the erythro- and leukocytic profile of the peripheral blood in rats]
Reports exposure-dependent blood changes; higher exposures produced hematologic alterations and liver and spleen findings.
1999 · Animal research
The mechanisms of the neurotropic action of bromantan
Experimental work examined dopamine, serotonin, and noradrenergic responses. These are mechanistic observations, not evidence of human cognitive or sleep benefits.
Rat neuroleptic antagonism · At 5 mg/kg
1996 · Comparison in people
Etomerzol during recovery from acute carbofos poisoning
The dissertation author reported normalized physical work capacity by days 7 vs 11 in moderate poisoning and days 10 vs 16 in severe poisoning. Pharmacokinetic estimates showed a longer half-life in the poisoning groups.
2012 · Animal research
Etomerzol and Metaprot after experimental poisoning in rats
The authors reported recovery of physical-load tolerance and changes in liver, kidney and oxidative-stress measures, including lower malondialdehyde and higher reduced glutathione.
2025 · Review of earlier studies
A review of Hypoxen pharmacology and potential to enhance sports performance
The review identifies a difficult-to-access Military Medical Academy literature from the 1980s–1990s and limited human evidence. It discusses several mitochondrial mechanisms rather than establishing a single oxygen-boosting effect.
2008 · Animal research
Accelerated utilization of lactate under the effect of hypoxen after intensive exercise
Hypoxen combined with energy-metabolism substrates was associated with higher lactate during maximal exercise, faster subsequent utilization and a lower recovery lactate/pyruvate ratio. The authors also describe an in-vitro NADH-oxidation pathway involving cytochrome c.
2010 · Lab research
The drug Hypoxen: a new inhibitor of mitochondrial respiration and dehydrogenases
Hypoxen reduced phosphorylating and uncoupled respiration, with substrate-dependent concentration thresholds. Malate, glutamate and succinate dehydrogenase activities decreased. This qualifies the claim that it uniformly increases mitochondrial respiration.
2010 · Lab research
Effect of Hypoxen on bioenergetic processes in mitochondria and ATP-sensitive potassium-channel activity
At low experimental concentrations, the authors report increased respiration, coupling, hydrogen-peroxide formation and potassium-associated mitochondrial swelling. ATP-related responses led them to propose involvement of mitochondrial ATP-sensitive potassium channels.
2012 · Comparison in people
Impact of Hypoxen therapy on postoperative course in gynecologic patients
An observational postoperative comparison reported less prolonged pain with adjunctive Hypoxen, but did not give pain-event counts or an effect size.
2002 · Animal research
Antimutagenic Hypoxen activity in vivo
Simultaneous injected Hypoxen reduced dioxidine-associated genotoxicity by a reported 35% over 24 hours. Five-day oral pretreatment did not reduce damage.
2012 · Animal research
Influence of Metaprot and Hypoxen on inflammatory-reaction development in an experiment
Hypoxen and Metaprot showed weak anti-inflammatory activity alone but enhanced aspirin-associated effects. The publisher abstract identifies Hypoxen plus aspirin as the most effective combination tested.
2004 · Animal research
Physiological mechanisms of chronic exposure to sulfur-containing gas in an experiment
The author’s conclusions report lower lipid-peroxidation, hypoxia and endogenous-intoxication markers and a shorter recovery period with Olifen. The industrial-gas context concerns the Astrakhan program, but the intervention evidence here is animal work.
2025 · Laboratory analysis
Urinary metabolites indicative of Hypoxen administration monitored by LC–HRMS/MS
The analytical study identified eight plausible Hypoxen-related urinary analytes. It provides markers for detecting administration, not evidence of improved endurance or clinical effectiveness.
2003 · Animal research
Etomerzol as an antioxidant agent
The original report describes effects on lipid peroxidation and antioxidant systems in rats, alongside laboratory oxidation assays.